Related Experiment Video
Updated: May 15, 2026
06:32
Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice
Published on: September 19, 2016
Vaccination against tuberculosis: how can we better BCG?
Jonathan M Pitt1, Simon Blankley, Helen McShane
1Division of Immunoregulation, MRC National Institute for Medical Research, The Ridgeway, Mill Hill, London NW7 1AA, UK.
Microbial Pathogenesis
|December 22, 2012
Summary
Tuberculosis is a major global health threat, causing thousands of deaths daily. New vaccines are needed to improve protection against tuberculosis beyond the current BCG vaccine.
Area of Science:
- Immunology
- Infectious Diseases
- Vaccinology
Background:
- Tuberculosis (TB) causes significant mortality, particularly in developing nations, with 3800 deaths daily.
- The current Bacillus Calmette-Guérin (BCG) vaccine offers insufficient protection against adult pulmonary tuberculosis, especially in high-burden regions.
- There is a critical need for novel vaccination strategies to enhance or replace BCG-induced immunity.
Purpose of the Study:
- To review current knowledge on immune responses to BCG and Mycobacterium tuberculosis.
- To identify challenges in developing new, more effective tuberculosis vaccines.
- To explore strategies for improved protection against tuberculosis infection and disease.
Main Methods:
- Literature review of immunological responses to Mycobacterium tuberculosis and BCG.
- Analysis of factors contributing to protective immunity against tuberculosis.
- Discussion of obstacles in tuberculosis vaccine development.
Main Results:
- The BCG vaccine's limitations in preventing adult pulmonary TB are highlighted.
- Understanding immune responses to Mycobacterium tuberculosis is crucial for vaccine design.
- Key challenges in developing effective tuberculosis vaccines are identified.
Conclusions:
- Enhanced understanding of protective immunity and pathogenic factors is essential.
- Accelerating the development of safe and effective tuberculosis vaccines is a priority.
- New vaccines are needed to restrict active tuberculosis and curb disease transmission.
More Related Videos
Related Concept Videos
01:28Pulmonary Tuberculosis V
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
01:26Pulmonary Tuberculosis IV
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
01:29Pulmonary Tuberculosis I
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
01:30Cancer Vaccines
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:51Vaccinations
Overview
01:28Pulmonary Tuberculosis II
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...